RxDoctor Payments Data

John Sokolowicz, MD

Cardiovascular Disease · Miami, FLNPI 1518067032

Payments from drug & device makers

$46,697in general payments, 2019–2025

Across 120 payments — averaging $389.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$36K
  • Vifor (international) Ltd.$8K
  • Johnson & Johnson$323
  • Biotronik Inc.$270
  • Sanofi-aventis U.S. LLC$234
  • AstraZeneca$195
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$2,02697%
  • Education$583%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,697 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$129,199
Medicare patients
1,567
Services billed
3,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$144,736
EntrestoSacubitril/Valsartan24$40,956
Repatha SureclickEvolocumab35$25,199
FarxigaDapagliflozin Propanediol11$16,162
BrilintaTicagrelor13$10,126
Repatha SyringeEvolocumab11$7,647
Metoprolol Succinate171$1,388
Nifedipine ErNifedipine60$1,349
Bumetanide26$1,247
Atorvastatin Calcium99$1,229
Rosuvastatin Calcium46$1,220
Losartan Potassium112$854
Atenolol16$636
ClopidogrelClopidogrel Bisulfate65$511
Metoprolol Tartrate102$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$144,736154 claims
NovartisEntresto$133$40,95624 claims
AstraZenecaFarxiga, Brilinta$195$26,28724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →